Africa's Cannabis Gold Rush: Who's Positioned to Lead Exports
Photo by NickyPe via Pixabay.
Trade data doesn't lie the way press releases sometimes do. In the first three months of 2026, South African exporters shipped 1,045 kilograms of medical cannabis flower into Germany, according to MJBizDaily's reporting on German import figures. That single quarter already puts the country on pace to beat its entire 2025 total of 3,725 kg. This is not a projection built on optimism or a government white paper promising future growth -- it's cargo that cleared customs, got tested, and landed on pharmacy shelves in Frankfurt and Munich. Germany's demand for imported medical cannabis is real, documented, and growing, and a cluster of African nations has spent the last several years positioning to supply it.
Ten African countries have passed laws legalizing medical or scientific cannabis production since roughly 2017: Lesotho, Zimbabwe, South Africa, Uganda, Malawi, Zambia, Ghana, Eswatini, Rwanda, and Morocco. That's a genuine wave of legislative activity, and it's tempting to read it as ten potential export powerhouses in waiting. But passing a law and building an export-ready supply chain are two completely different undertakings, separated by years of capital investment, regulatory plumbing, and compliance testing that most of these countries haven't come close to completing. The question worth asking isn't who legalized cannabis first -- it's which of these ten have actually built the EU-GMP certified facilities, the licensing infrastructure, and the capital base needed to turn a legal framework into a recurring export revenue stream. That's the question this piece tries to answer.
South Africa's Bid for Export Leadership
South Africa's claim to continental export leadership rests on numbers that are unusually verifiable for this industry. The 1,045 kg shipped to Germany in Q1 2026 alone represents better than a quarter of last year's full-year total of 3,725 kg, and if that quarterly pace holds, 2026 will close out well ahead of 2025. That's not a forecast built on sentiment -- it's a straight-line extrapolation from a single data point, and it should be read with the appropriate caution, but the direction is clear enough that industry players are already repositioning around it.
Johan Slabber, CEO of Nexus Pharma, has framed South Africa's strategy explicitly as competing on quality rather than price against entrenched exporters like Canada and the Netherlands. That's a telling strategic choice, because it concedes South Africa can't win a race-to-the-bottom cost war against lower-regulation producers, and instead bets on pharmaceutical-grade consistency as the differentiator that gets a supplier onto a German formulary.
The regulatory scaffolding backs that ambition up, at least on paper. The Department of Agriculture has issued 1,408 cultivation permits, while the South African Health Products Regulatory Authority (SAHPRA) has granted roughly 120 medical cultivation and export licences, with 93 licensed establishments reported active as of February 2025. But the real filter sits one level deeper: Section 22C medicinal approvals require facilities built to EU-GMP standards, which in South Africa means capital outlays of R25 to R280 million and 12 to 24 months of build-out time before a single gram can legally cross a border. That cost structure quietly does the work of separating serious operators from speculative ones -- most of those 1,408 agricultural permit holders will never clear the GMP bar.
Policy coordination is the other piece South Africa has that most peers lack. A National Cannabis Master Plan is being coordinated across four government departments, a Hemp and Cannabis Commercialisation Policy is expected before Cabinet by April 2026, and an Overarching Cannabis Bill is targeted for Parliament by mid-2027. The Plant Improvement Act, in force since December 1, 2025, now permits commercial hemp cultivation, import and export under permit for material at or below 2% THC, filling a gap that previously left hemp in a legal gray zone. Domestic market figures of R28-36 billion do circulate, but they trace back to industry and PR-adjacent sources rather than primary government statistics, and deserve real skepticism until a government agency publishes its own number.
Lesotho: The Pioneer Under New Pressure
Lesotho got here first, and it's worth remembering that in 2017 it became the first African nation to legalize medical cannabis cultivation -- a framework that covered manufacture, distribution, import and export in one piece of legislation, years before South Africa's regulatory machinery caught up. The country's National Development Corporation has claimed annual exports in the range of USD 15-20 million, broken down roughly as 65% dried flower, 25% high-value extracts, and 10% seeds. Take that split as industry-reported rather than independently audited, but it's a plausible mix for a market that's had nearly a decade to mature.
That head start is now colliding with a harder regulatory environment. A 2025 amendment tightened import and export permit requirements and introduced stricter lab testing obligations, pushing Lesotho's compliance regime closer to what buyers in Germany actually expect. A June 2026 industry analysis pegs the up-front cost of an operator licence at M400,000 (the loti is pegged one-to-one with the South African rand) -- a steep jump from what earlier entrants paid, and one that risks squeezing out the smaller domestic growers who built the industry's first decade.
There's a genuine fork in the road here, and it's not obvious which way it resolves. Tighter compliance and costlier licences could be exactly what Lesotho needs to hit EU-grade consistency and go toe-to-toe with South African exporters on quality. Or it could do the opposite: consolidate the industry around a handful of larger, often foreign-backed operators with the capital to absorb M400,000 licence fees, while the small growers who proved out Lesotho's model in the late 2010s get priced out entirely. Both outcomes are plausible from the same policy change, and which one dominates will depend on how SAHPRA-equivalent enforcement actually plays out over the next two or three licensing cycles.
Lesotho's nine-year head start is a real advantage -- established buyer relationships, a working export logistics chain, a lower cost base than South Africa's R25-280 million GMP build-outs. But South Africa's larger capital markets, deeper diplomatic engagement with the EU, and coordinated national policy apparatus give it the resources to close that gap within this mid-term window, even starting from behind.
The Rest of the Field: Uganda, Morocco, and the Next Wave
Beyond South Africa and Lesotho, the remaining eight countries on the ten-nation list -- Zimbabwe, Uganda, Malawi, Zambia, Ghana, Eswatini, Rwanda, and Morocco -- sit at genuinely different stages of maturity, and lumping them together obscures more than it reveals.
Uganda's approach so far looks like a controlled pilot rather than an open market. In July 2025 the government granted an experimental licence to Bright Sparks Farm Limited to cultivate, process and export medicinal cannabis across the Nakasongola and Luweero Districts, with the operation conducted under police supervision. That's a meaningfully different regulatory posture than South Africa's permit-based system -- it signals a government testing the waters with a single, closely watched operator rather than opening licensing broadly. Whether Uganda scales that model or keeps it as a one-off experiment will say a lot about how fast it can move.
Morocco is the more interesting wildcard. It legalized cultivation for medical and industrial use in 2021, and it's trying to leverage something none of the other nine countries have: the Rif region's centuries-old reputation as a hashish-producing area, with deep, if informal, cultivation expertise already embedded in the local economy. Geographically, Morocco also sits far closer to European ports and regulators than South Africa or Lesotho, which matters for logistics and shipping times. The challenge is converting that informal, traditional economy into facilities that can pass EU-GMP inspection -- a transition that requires formalizing supply chains that have operated outside state oversight for generations, which is a slower and more politically delicate process than building a greenfield facility from scratch.
The other six -- Zimbabwe, Malawi, Zambia, Ghana, Eswatini, and Rwanda -- have legal frameworks on the books, but public data on export volumes and active licensing infrastructure in these markets remains thin, suggesting they're years behind South Africa and Lesotho on the metrics that actually matter. This pattern isn't unique to Africa. Canada's and the Netherlands' export markets went through the same filtering process roughly a decade ago, where dozens of licensed producers existed on paper but EU-GMP certification turned out to be the real gatekeeper that determined who actually shipped product into Europe. Legalization is step one in a much longer process, and most of the field hasn't reached step two yet.
Why Germany Is the Prize Everyone's Chasing
South Africa's cannabis exports to Germany are projected to grow from 3,725 kg in 2025 to about 4,200 kg by the end of 2026, with Q1 2026 already reaching 1,045 kg, signaling continued expansion of the trade.
Germany didn't become the benchmark market by accident. Its 2024 partial legalization of adult-use cannabis, layered on top of an existing medical cannabis import framework, created a demand signal sustained enough that exporters across two continents are now actively competing to fill it. Both South Africa's and Lesotho's export performance are measured, in practice, against German import statistics -- it's the one dataset specific enough and public enough to use as a real benchmark, which is exactly why MJBizDaily's reporting on it carries weight.
It's worth being clear-eyed about what African producers are actually walking into: not an open field, but a market with established incumbents. Canada, the Netherlands, Portugal, and North Macedonia already supply Germany at volume, with years of buyer relationships, logistics networks, and regulatory track records already built. South African and Lesotho exporters aren't discovering a greenfield opportunity -- they're entering a competitive market against suppliers who got there first and have already absorbed the fixed costs of EU-GMP certification.
That's exactly why Nexus Pharma's Slabber frames South Africa's play as a quality competition rather than a price war. Undercutting Canadian or Dutch suppliers on cost is the obvious move for a new entrant, but it's also the move that invites a race to the bottom nobody actually wins long-term -- margins compress, quality standards get tested, and the whole category risks a reputational hit if a low-cost supplier has a testing failure. Competing on consistency and pharmaceutical-grade reliability is slower to pay off, since it requires building a buyer's trust over multiple shipment cycles rather than winning on a spreadsheet, but it's the more durable position once established.
The open question that will determine how this plays out over the next several years is straightforward: does German demand keep expanding fast enough to absorb new African supply on top of what Canada, the Netherlands, Portugal and North Macedonia already provide, or does it plateau? If German consumption keeps climbing -- driven by broader medical prescribing and the knock-on effects of adult-use normalization -- there's room for new entrants to grow alongside incumbents. If it plateaus, new African volume start displacing existing suppliers, and that's a genuinely different, more adversarial competitive dynamic than the one South Africa and Lesotho appear to be planning around.
What the Market Size Actually Suggests -- and the Grain of Salt
Photo by MART PRODUCTION via Pexels.
IMARC Group projects Africa's medical cannabis market growing from USD 1.9 billion in 2025 to USD 8.2 billion by 2034, implying a 17.2% compound annual growth rate. That's a substantial trajectory, and it's worth noting where the historical parallel comes from rather than taking the number on faith: a growth curve in that range roughly matches what North American medical cannabis markets experienced in the early 2010s, before recreational legalization in states like Colorado and Washington accelerated the category further. The parallel is informative, not predictive -- it tells us this kind of growth rate has happened before in an analogous early-stage medical market, not that Africa's will definitely follow the same path.
Several concrete risk factors could knock that trajectory off course. Currency volatility is the most immediate one: the rand has a history of sharp swings, the loti is pegged one-to-one to it, and other African currencies in this group carry their own instability, which makes R25-280 million EU-GMP build-outs meaningfully riskier for foreign investors financing in euros or dollars. Slow bureaucratic permitting is another -- South Africa's own Overarching Cannabis Bill timeline has already stretched from earlier expectations out to mid-2027, and government coordination across four departments is the kind of process that reliably runs long. And there's the demand-side risk: if Europe's own cannabis consumption growth underwhelms relative to current projections, the pull driving South African and Lesotho export growth weakens regardless of how good African supply chains become.
The single biggest swing factor sits in German politics. Germany's adult-use reform is relatively new, politically contested, and not immune to reversal or stalling if a future coalition government takes a harder line -- and given that German import data is the yardstick this whole African export narrative is measured against, a political reversal there would ripple back through every projection in this piece.
Putting it together, the honest read is that South Africa currently holds the clearest near-term lead on paper -- more permits, more coordinated policy, deeper capital access -- but Lesotho's nine-year operating track record and lower cost base, plus Morocco's geographic proximity to Europe and generations of Rif-region cultivation expertise, mean nobody has locked up continental leadership yet. This is a competition still very much in its opening rounds.
Strip away the press releases and the pattern across all ten countries is consistent: legalization has sprinted ahead of export infrastructure almost everywhere on the continent. The real competition over the next three to seven years won't be decided by who passed a cannabis law first -- Lesotho already won that race in 2017 and it hasn't translated into continental dominance. It'll be decided by who builds EU-GMP certified capacity fastest, finances it through currency volatility, and keeps a clean enough compliance record that German buyers keep renewing contracts.
There are two concrete markers worth actually tracking rather than guessing at over this period. First, South Africa's Overarching Cannabis Bill, targeted for Parliament by mid-2027 -- if it slips the way these timelines often do, it tells you something real about how much the Master Plan's four-department coordination is actually working versus just existing on paper. Second, whether Lesotho's 2025 fee hikes and tightened testing requirements end up consolidating the industry around a handful of better-capitalized operators, or whether enough small growers survive the transition to keep the sector's original character intact. Both are checkable facts, not predictions dressed up as facts.
The scenario that matters most, though, is the shape of German demand itself. If it keeps climbing the way it has through early 2026, there's plausibly room for South Africa, Lesotho, and even an emerging Morocco to all grow their export volumes simultaneously without directly cannibalizing each other -- a rising market can support multiple winners. If German demand plateaus instead, this turns into something closer to zero-sum: South Africa's capital advantage and Lesotho's cost advantage end up fighting over a fixed slice of import volume, and that's a much less comfortable position for everyone currently building toward 2027 and beyond.
Sources
